Abstract
Thirty-four patients resistant to cyclophosphamide and Adriamycin received hexamethylmelamine at one of two dose regimens: 6 mg/kg/day orally for 21 days every 4 weeks or 8 mg/kg/day orally for 21 days every 6 weeks. Only five patients responded. Tolerance to the drug was, however, satisfactory; nausea, pyrosis, and vomiting were the only frequent side effects. Myelosuppression occurred in only one case.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Altretamine / administration & dosage*
-
Cyclophosphamide / therapeutic use*
-
Doxorubicin / therapeutic use*
-
Drug Administration Schedule
-
Drug Resistance
-
Female
-
Humans
-
Middle Aged
-
Ovarian Neoplasms / drug therapy*
-
Triazines / administration & dosage*
Substances
-
Triazines
-
Doxorubicin
-
Cyclophosphamide
-
Altretamine